通过小分子对帕金森病的选择性共价抑制JNK3
Wen Shuai1, Panpan Yang1, Huan Xiao1
1State Key Laboratory of Biotherapy and Cancer Center, Innovation Center of Nursing Research, West China Hospital, Sichuan University, No. 17, Section 3, Renmin South Road, 610041, Chengdu, China.
Angewandte Chemie (International ed. in English)
|September 14, 2024
概括
研究人员开发了一种选择性共价抑制剂,JC16I,针对帕金森氏症等神经退行性疾病的JNK3. 这种抑制剂显示出高选择性和神经保护作用,提供了一个新的治疗途径.
科学领域:
- 生物化学 生物化学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- c-Jun N-终端激酶 (JNKs),特别是JNK3,在大脑中至关重要,并代表神经退行性疾病的治疗点.
- 开发用于研究和治疗应用的选择性JNK3抑制剂是具有挑战性的,因为在JNK家族中保留了氨酸残留物.
研究的目的:
- 用一种共价药物设计策略识别一种JNK3选择性共价抑制剂.
- 在帕金森病模型中评估抑制剂的疗效,选择性和神经保护潜力.
主要方法:
- 采用了共价策略来设计和合成JNK3选择性共价抑制剂JC16I.
- 在细胞模型中评估了JC16I对JNK1/2的选择性及其抑制活性.
- 利用含有基因的探针 (JC-P1) 在细胞溶解物和活细胞中标记JNK3.
- 在帕金森病模型中研究了JC16I对JNK3信号传递的影响及其神经保护能力.
主要成果:
- 与JNK1/2.2相比,JC16I显示出对JNK3的高抑制活性,选择性超过160倍.
- 即使在低度下,JC16I也表现出细胞JNK3的增强和长期抑制.
- 探测器JC-P1在细胞溶解物和活细胞中选择性地标记了JNK3,具有良好的全蛋白质组选择性.
- 在帕金森病模型中,JC16I有效抑制了异常的JNK3信号,并提供神经保护.
结论:
- 联药物设计针对保存的囊蛋白是一种可行的策略,用于开发异形选择性,细胞活性JNK3抑制剂.
- JC16I作为一个有价值的化学探针用于体外和体内JNK3研究.
- 这种方法为帕金森病和其他神经退行性疾病开辟了新的治疗途径.
更多相关视频
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
518
11:31Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate
Published on: September 18, 2013
10.0K
相关概念视频
01:20The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
01:24Parkinson's Disease: Treatment
237
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
237
01:07MAPK Signaling Cascades
5.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.3K
02:26NF-κB-dependent Signaling Pathway
7.4K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.4K